Geromedicine
How aging biology, biomarkers, and geroscience research translate into practical clinical decisions today.
Rapamycin in Human Clinical Trials: What the Evidence Actually Shows
Does rapamycin actually slow aging in humans? A physician breaks down mTOR biology, the PEARL trial, immune rejuvenation data, and the side effects of off-label use.
What Is Intrinsic Capacity? The Metric Transforming Preventive Geromedicine
What is intrinsic capacity? A physician explains the WHO framework measuring physical and mental reserve, its core domains, and how it is transforming preventive geromedicine.
Acarbose as a Gerotherapeutic: What the ITP Data and Clinical Trials Actually Show
Why did acarbose extend male mouse lifespan by 22% in NIA trials? A physician examines the ITP data, human diabetes prevention, and clinical cardiovascular outcomes.
Senolytics in Geroscience: Can Clearing "Zombie Cells" Improve Human Healthspan?
Can clearing senescent cells slow biological aging? A physician explores the mechanisms, clinical trials, benefits, and risks of senolytics in geroscience.
The Whack-a-Mole Problem in Modern Medicine: Why the Future of Healthcare Depends on Geroscience
Why does modern medicine treat diseases in isolation? A physician explains the geroscience hypothesis, morbidity compression, and why funding basic aging biology is essential.
SGLT2 Inhibitors as Gerotherapeutics: From Diabetes Medications to Longevity Candidates
Can diabetes drugs slow biological aging? A physician breaks down SGLT2 inhibitors, their preclinical lifespan data, hallmarks of aging, and human clinical trials.
From Bench to Bedside: How We Safely Evaluate Gerotherapeutics in Clinical Practice
How do physicians evaluate anti-aging drugs? A physician breaks down the clinical evidence for GLP-1s, SGLT2 inhibitors, Rapamycin, Metformin, and Fasting-Mimicking Diets in healthspan practice.
When Should You Start a Gerotherapeutic? The Timing Paradox in Longevity Medicine
When should you start a gerotherapeutic? A physician breaks down antagonistic pleiotropy, dosing nuances, why starting too early carries real trade-offs, and the middle-age hypothesis.
Biological Age Tests and Epigenetic Clocks: What the Science Shows (And What It Can't Tell You)
Are direct-to-consumer biological age tests worth it? A physician breaks down how epigenetic clocks work, what the science proves, and why they currently lack clinical utility.
Therapeutic Plasma Exchange and Plasma Dilution: Separating Geroscience from Commercial Hype
Is plasma exchange a true geroscience breakthrough or commercial hype? A physician breaks down neutral plasma dilution, the AMBAR trial, epigenetic clock data in healthy adults, and safety considerations.
Metformin as a Gerotherapeutic: Science, Promise, and Clinical Realities
Is metformin a true anti-aging drug or a metabolic medication? A physician breaks down the science, mouse ITP trials, exercise interaction data, and long-term mortality studies.
GLP-1 RAs as Gerotherapeutics: Cardiometabolic Breakthrough or True Anti-Aging Therapy?
Are GLP-1 RAs like semaglutide true gerotherapeutics? A physician breaks down the evidence for inflammation reduction, cardiovascular protection, muscle quality nuances, and clinical protocols.
Rapamycin: The Preclinical Evidence, Human Studies, and Clinical Unknowns
Rapamycin is heavily discussed in geroscience, but what do human trials actually show? A physician breaks down mTOR biology, the ITP mouse studies, PEARL trial results, and key safety risks.
What Is Geromedicine? Where the Science of Aging Actually Stands
What is geromedicine? A physician breaks down geroscience, the hallmarks of aging, translational challenges in human trials, and what the evidence actually says about candidate anti-aging therapies.